{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:06:01Z","timestamp":1788231961582,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Continuous subcutaneous foslevodopa\/foscarbidopa infusion (CSFLI) is a novel non\u2010surgical alternative to levodopa\/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real\u2010world switch data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non\u2010motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ\u20108 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70317","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:16:32Z","timestamp":1756116992000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Switching from Levodopa\/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa\/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series"],"prefix":"10.1002","volume":"13","author":[{"given":"Guillaume","family":"Baille","sequence":"first","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Patte\u2010Karsenti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Salardaine","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"de Saint\u2010Vaulry","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Philippe","family":"Brandel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-9590","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Desjardins","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fondation Rothschild Hospital Paris Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9439-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.9.1131"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13675"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26123"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221108018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.03.012"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.24247"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14161"},{"key":"e_1_2_9_13_1","first-page":"1","article-title":"Real\u2010world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations","author":"Koeglsperger T","year":"2025","journal-title":"J Neural Transm"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70077"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.24114"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70060"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:12:59Z","timestamp":1773029579000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/mdc3.70317"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70317","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"2025-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}